Tin tức & Cập nhật

Adjunctive azithromycin use during unscheduled cesarean deliveries has increased following the landmark C/SOAP trial in 2016, resulting in a decrease in postpartum infection rates in a real-world US cohort.

In the phase III PROPEL 3 trial, once-daily treatment with infigratinib results in a significantly greater increase in annualized height velocity (AHV) in children with achondroplasia.

The selective, oral, central nervous system-penetrant reversible RIPK1 inhibitor SAR443820 appears to have limited clinical benefit in amyotrophic lateral sclerosis (ALS) and is even associated with greater hepatic enzyme increase, according to the phase II HIMALAYA trial.

Treatment with aficamten significantly improves patient-reported health status and exercise capacity in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM), according to the ACACIA-HCM trial presented at ESC 2026.

Treatment with tirzepatide does not appear to be associated with atrial fibrillation or atrial arrhythmia in individuals with overweight or obesity, according to a meta-analysis.

In individuals with untreated HIV-1 infection, the two-drug dolutegravir/lamivudine (DTG/3TC) antiretroviral therapy (ART) regimen has similar efficacy as the three-drug bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen, according to the phase IIIb VOGUE study.

Patterns of thyroid-stimulating hormone (TSH) test show no substantial difference between type 2 diabetes patients treated with GLP-1 RAs and those who received SGLT-2 inhibitors, a study has found.

The novel oral orexin 2 receptor (OX2R) agonist alixorexton has demonstrated clinical benefits in patients with narcolepsy type 1, yielding improvements in wakefulness, excessive daytime sleepiness, and cataplexy, according to the phase II Vibrance-1 trial.